Omega Fund Management, LLC Q4 2025 Filing
Filed February 17, 2026
Portfolio Value
$286.5B
Holdings
11
Report Date
Q4 2025
Filing Type
13F-HR
All Holdings (11 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | NUVBNuvation Bio | 8,081,089 | $72.4B | 25.27% | |
| 2 | BBOTBridgeBio Oncology Therapeutics Inc. | 3,289,661 | $41.2B | 14.37% | |
| 3 | BBNXBeta Bionics Inc. | 1,316,183 | $40.1B | 14.00% | |
| 4 | BCAXBicara Therapeutics Inc. | 2,204,650 | $37.1B | 12.95% | |
| 5 | KMTSKestra Med Technologies Ltd | 1,373,591 | $36.4B | 12.71% | |
| 6 | UPBUpstream Bio Inc. | 1,326,293 | $36.0B | 12.57% | |
| 7 | ENGNenGene Holdings Inc. | 876,357 | $7.9B | 2.76% | |
| 8 | ALMSAlumis Inc. | 653,223 | $6.4B | 2.22% | |
| 9 | SANASana Biotechnology, Inc. | 843,750 | $3.4B | 1.20% | |
| 10 | IMAImageneBio, Inc. | 455,361 | $3.1B | 1.10% | |
| 11 | REPLReplimune Group | 248,672 | $2.4B | 0.84% |